Myelodysplastic Syndrome (MDS) Drugs Market Size, Share & Trends Analysis By Therapeutic Class (Hypomethylating Agents, Immunomodulatory Drugs, Anti-anemics), And Segment Forecasts, 2016 - 2022
This report can be delivered to the clients within 48 Business Hours
The global myelodysplastic syndrome (MDS) drugs market size is expected to reach USD 2.4 billion by 2022, according to a new report by Grand View Research, Inc., exhibiting a 9.7% CAGR during the forecast period. Factors such as strong product pipeline, rising geriatric population, and favorable government initiatives are driving the market.
MDS is caused by mutation of one or more genes that control development of blood cells. Patients with this condition may present with clinical manifestations such as thrombocytopenia, neutropenia, and anemia. Although majority of cases (over 90%) are reported in people over the age of 60, the condition can occur at any age, more frequently in men than in women. About 30% of MDS cases advance to acute myeloid leukemia (AML).
The immunomodulatory drug segment is expected to retain its dominant position in the MDS drugs market due to strong sales of Revlimid. Supported by potential approvals of luspatercept and Aranesp, the anti-anemics drug segment is forecast to gain higher market share than hypomethylating agents, thus contributing significantly to the overall expansion of the market.
Developing novel drugs for the treatment of rare subsets of MDS patients is a key challenge as the disease is highly heterogeneous at the molecular level. In addition, morbidity issues and poor quality of life due to incapacitating effects of the standard of care treatment paradigms are causes of inconvenience for geriatric population.
Further key findings from the report suggest:
The global myelodysplastic syndrome (MDS) drugs market size is expected to reach USD 2.4 billion by 2022, according to a new report by Grand View Research, Inc., exhibiting a 9.7% CAGR during the forecast period. Factors such as strong product pipeline, rising geriatric population, and favorable government initiatives are driving the market.
MDS is caused by mutation of one or more genes that control development of blood cells. Patients with this condition may present with clinical manifestations such as thrombocytopenia, neutropenia, and anemia. Although majority of cases (over 90%) are reported in people over the age of 60, the condition can occur at any age, more frequently in men than in women. About 30% of MDS cases advance to acute myeloid leukemia (AML).
The immunomodulatory drug segment is expected to retain its dominant position in the MDS drugs market due to strong sales of Revlimid. Supported by potential approvals of luspatercept and Aranesp, the anti-anemics drug segment is forecast to gain higher market share than hypomethylating agents, thus contributing significantly to the overall expansion of the market.
Developing novel drugs for the treatment of rare subsets of MDS patients is a key challenge as the disease is highly heterogeneous at the molecular level. In addition, morbidity issues and poor quality of life due to incapacitating effects of the standard of care treatment paradigms are causes of inconvenience for geriatric population.
Further key findings from the report suggest:
- An estimated 60,000 people in U.S. are living with myelodysplastic syndrome, with approximately 10,000-15,000 new cases being reported annually
- U.S. dominated the global MDS drugs market with more than 48.0% share in 2016 owing to rising disease incidence and launch of strong pipeline candidates
- Emerging markets such as India, China, and South Korea are expected to exhibit lucrative growth during the forecast period due to favorable government policies, rising awareness about hematological malignancies, increased investment, and improved healthcare infrastructure
- Immunomodulatory drugs led the drug classes with a market share of more than 54.0% in 2016. Hypomethylating agents are projected to witness a double-digit decline in market share due to expected patent expirations
- Celgene, Amgen, Otsuka, and Takeda are some of the key players operating in this area; Celgene accounted for 95.2% of the market in 2016, driven by strong sales of Revlimid and Vidaza
- Currently, there are about 45 pipeline drugs in various stages of clinical development. Promising pipeline candidates such as Aranesp, luspatercept, Vyxeos, guadecitabine, and pevonedistat are expected to generate significant revenue upon launch.
CHAPTER 1 RESEARCH METHODOLOGY
1.1 Information Procurement
1.2 Information or Data Analysis
1.2.1 Market formulation & validation
CHAPTER 2 EXECUTIVE SUMMARY
CHAPTER 3 DISEASE PRIMER AND EPIDEMIOLOGY
3.1 Disease Primer
3.1.1 Types
3.1.2 Epidemiology
3.1.3 Current prevalence and incidence for seven major markets (U.S., Japan, EU5)
CHAPTER 4 GLOBAL MARKET OVERVIEW
4.1 Market by Treatment
4.1.1 Supportive Therapy
4.1.1.1 Blood transfusions
4.1.1.2 Iron chelation therapy
4.1.1.3 Growth factors
4.1.2 Chemotherapy
4.1.3 Stem cell transplantation
4.2 Market by Therapeutic Class
4.2.1 Hypomethylating agents
4.2.2 Immunomodulatory drugs
4.2.3 Anti-anemics
4.3 Market Size & Forecast
4.4 Sales Performance
4.4.1 Sales performance, by drug class (2016 - 2022)
4.4.2 Sales performance, by countries (2016 - 2022)
4.4.3 Sales performance, by company (2016 - 2022)
4.5 Market Share Distribution
4.6 Market Dynamics and Brand Strategies
4.7 Patent Expiry Schedule
4.8 Drivers and Challenges
4.9 M&A, Deal Landscape (2013-2017 YTD)
4.10 Pricing and Reimbursement
4.11 SWOT
CHAPTER 5 PIPELINE INTELLIGENCE
5.1 Pipeline Landscape
5.1.1 Leading drugs in development
5.1.2 Key R&D trends
5.2 Promising Drug Candidates in Pipeline
5.2.1 Late stage pipeline analysis
5.2.2 Profile of disruptive drugs
5.2.2.1 Luspatercept (ACE-536)
5.2.2.2 Aranesp (Darbepoetin alfa)
5.3 Global Pipeline Forecast
CHAPTER 6 COMPETITIVE LANDSCAPE
6.1 Celgene
6.1.1 Company overview
6.1.2 Current product portfolio-Major products
6.1.3 Product forecast sales up to 2022
6.1.4 Strategic initiatives (Celgene)
6.1.4.1 Key company news flow
6.1.5 Pipeline overview
6.1.6 SWOT
6.2 Amgen
6.2.1 Company overview
6.2.2 Current product portfolio-Major products
6.2.3 Product forecast sales up to 2022
6.2.4 Strategic initiatives (Amgen)
6.2.4.1 Key company news flow
6.2.5 Pipeline analysis & overview
6.2.6 SWOT
6.3 Otsuka
6.3.1 Company overview
6.3.2 Current product portfolio-Major products
6.3.3 Product forecast sales up to 2022
6.3.4 Strategic initiatives (Otsuka)
6.3.4.1 Key company news flow
6.3.5 Pipeline analysis & overview
6.3.6 SWOT
6.4 Takeda
6.4.1 Company overview
6.4.2 Current roduct portfolio-Major products
6.4.3 Product forecast sales up to 2022
6.4.4 Strategic initiatives (Takeda)
6.4.4.1 Key company news flow
6.4.5 Pipeline analysis & overview
6.4.6 SWOT
CHAPTER 7 MARKET OUTLOOK
7.1 What the future holds
7.2 Winners and losers
7.3 Emerging companies
7.4 The road ahead
1.1 Information Procurement
1.2 Information or Data Analysis
1.2.1 Market formulation & validation
CHAPTER 2 EXECUTIVE SUMMARY
CHAPTER 3 DISEASE PRIMER AND EPIDEMIOLOGY
3.1 Disease Primer
3.1.1 Types
3.1.2 Epidemiology
3.1.3 Current prevalence and incidence for seven major markets (U.S., Japan, EU5)
CHAPTER 4 GLOBAL MARKET OVERVIEW
4.1 Market by Treatment
4.1.1 Supportive Therapy
4.1.1.1 Blood transfusions
4.1.1.2 Iron chelation therapy
4.1.1.3 Growth factors
4.1.2 Chemotherapy
4.1.3 Stem cell transplantation
4.2 Market by Therapeutic Class
4.2.1 Hypomethylating agents
4.2.2 Immunomodulatory drugs
4.2.3 Anti-anemics
4.3 Market Size & Forecast
4.4 Sales Performance
4.4.1 Sales performance, by drug class (2016 - 2022)
4.4.2 Sales performance, by countries (2016 - 2022)
4.4.3 Sales performance, by company (2016 - 2022)
4.5 Market Share Distribution
4.6 Market Dynamics and Brand Strategies
4.7 Patent Expiry Schedule
4.8 Drivers and Challenges
4.9 M&A, Deal Landscape (2013-2017 YTD)
4.10 Pricing and Reimbursement
4.11 SWOT
CHAPTER 5 PIPELINE INTELLIGENCE
5.1 Pipeline Landscape
5.1.1 Leading drugs in development
5.1.2 Key R&D trends
5.2 Promising Drug Candidates in Pipeline
5.2.1 Late stage pipeline analysis
5.2.2 Profile of disruptive drugs
5.2.2.1 Luspatercept (ACE-536)
5.2.2.2 Aranesp (Darbepoetin alfa)
5.3 Global Pipeline Forecast
CHAPTER 6 COMPETITIVE LANDSCAPE
6.1 Celgene
6.1.1 Company overview
6.1.2 Current product portfolio-Major products
6.1.3 Product forecast sales up to 2022
6.1.4 Strategic initiatives (Celgene)
6.1.4.1 Key company news flow
6.1.5 Pipeline overview
6.1.6 SWOT
6.2 Amgen
6.2.1 Company overview
6.2.2 Current product portfolio-Major products
6.2.3 Product forecast sales up to 2022
6.2.4 Strategic initiatives (Amgen)
6.2.4.1 Key company news flow
6.2.5 Pipeline analysis & overview
6.2.6 SWOT
6.3 Otsuka
6.3.1 Company overview
6.3.2 Current product portfolio-Major products
6.3.3 Product forecast sales up to 2022
6.3.4 Strategic initiatives (Otsuka)
6.3.4.1 Key company news flow
6.3.5 Pipeline analysis & overview
6.3.6 SWOT
6.4 Takeda
6.4.1 Company overview
6.4.2 Current roduct portfolio-Major products
6.4.3 Product forecast sales up to 2022
6.4.4 Strategic initiatives (Takeda)
6.4.4.1 Key company news flow
6.4.5 Pipeline analysis & overview
6.4.6 SWOT
CHAPTER 7 MARKET OUTLOOK
7.1 What the future holds
7.2 Winners and losers
7.3 Emerging companies
7.4 The road ahead
LIST OF TABLES
Table 1 Sales Performance, by Drug Class (in $ million)
Table 2 Sales Performance, by Countries (in $ million)
Table 3 Sales Performance, by Company (in $ million)
Table 4 Patent Expiry Schedule
Table 5 R&D Pipeline Overview
Table 6 Late Stage Pipeline
Table 7 Product Profile: Luspatercept (ACE-536)
Table 8 Product Profile: Aranesp (Darbepoetin alfa)
Table 9 Global Pipeline Forecast
Table 10 Product Portfolio: Vidaza
Table 11 Product Portfolio: Revlimid
Table 12 Product Portfolio: Luspatercept
Table 13 Vidaza Sales Forecast, 2016 - 2022 (in $ million)
Table 14 Revlimid Sales Forecast, 2016 - 2022 (in $ million)
Table 15 Luspatercept Sales Forecast, 2016 - 2022 (in $ million)
Table 16 Pipeline (Celgene)
Table 17 Product Portfolio: Aranesp
Table 18 Aranesp Sales Forecast, 2016 - 2022 (in $ million)
Table 19 Pipeline (Amgen)
Table 20 Product Portfolio: Dacogen
Table 21 Product Portfolio: Guadecitabine
Table 22 Guadecitabine Sales Forecast, 2016 - 2022 (in $ million)
Table 23 Pipeline (Otsuka)
Table 24 Product Portfolio: Pevonedistat
Table 25 Pevonedistat Sales Forecast, 2016 - 2022 (in $ million)
Table 26 Pipeline (Takeda)
Table 1 Sales Performance, by Drug Class (in $ million)
Table 2 Sales Performance, by Countries (in $ million)
Table 3 Sales Performance, by Company (in $ million)
Table 4 Patent Expiry Schedule
Table 5 R&D Pipeline Overview
Table 6 Late Stage Pipeline
Table 7 Product Profile: Luspatercept (ACE-536)
Table 8 Product Profile: Aranesp (Darbepoetin alfa)
Table 9 Global Pipeline Forecast
Table 10 Product Portfolio: Vidaza
Table 11 Product Portfolio: Revlimid
Table 12 Product Portfolio: Luspatercept
Table 13 Vidaza Sales Forecast, 2016 - 2022 (in $ million)
Table 14 Revlimid Sales Forecast, 2016 - 2022 (in $ million)
Table 15 Luspatercept Sales Forecast, 2016 - 2022 (in $ million)
Table 16 Pipeline (Celgene)
Table 17 Product Portfolio: Aranesp
Table 18 Aranesp Sales Forecast, 2016 - 2022 (in $ million)
Table 19 Pipeline (Amgen)
Table 20 Product Portfolio: Dacogen
Table 21 Product Portfolio: Guadecitabine
Table 22 Guadecitabine Sales Forecast, 2016 - 2022 (in $ million)
Table 23 Pipeline (Otsuka)
Table 24 Product Portfolio: Pevonedistat
Table 25 Pevonedistat Sales Forecast, 2016 - 2022 (in $ million)
Table 26 Pipeline (Takeda)
LIST OF FIGURES
Fig. 1 Market research process
Fig. 2 Information Procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value chain based sizing & forecasting
Fig. 6 QFD modelling for market share assessment
Fig. 7 MDS Age-Adjusted Incidence Rates, per 100,000 Population, by Race - 2014
Fig. 8 MDS Age-Adjusted Incidence Rates, per 100,000 Population, by Age - 2014
Fig. 9 Myelodysplastic Syndrome Drugs Market by Therapeutic Class (2016 & 2022)
Fig. 10 Myelodysplastic Syndrome Drugs Market, $ million (2016 & 2022)
Fig. 11 Market Share Distribution (2016 & 2022)
Fig. 12 Regional Share Distribution (2016 & 2022)
Fig. 13 Myelodysplastic Syndrome Drugs Market SWOT
Fig. 14 SWOT Analysis (Celgene)
Fig. 15 SWOT Analysis (Amgen)
Fig. 16 SWOT Analysis (Otsuka)
Fig. 17 SWOT Analysis (Takeda)
Fig. 1 Market research process
Fig. 2 Information Procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value chain based sizing & forecasting
Fig. 6 QFD modelling for market share assessment
Fig. 7 MDS Age-Adjusted Incidence Rates, per 100,000 Population, by Race - 2014
Fig. 8 MDS Age-Adjusted Incidence Rates, per 100,000 Population, by Age - 2014
Fig. 9 Myelodysplastic Syndrome Drugs Market by Therapeutic Class (2016 & 2022)
Fig. 10 Myelodysplastic Syndrome Drugs Market, $ million (2016 & 2022)
Fig. 11 Market Share Distribution (2016 & 2022)
Fig. 12 Regional Share Distribution (2016 & 2022)
Fig. 13 Myelodysplastic Syndrome Drugs Market SWOT
Fig. 14 SWOT Analysis (Celgene)
Fig. 15 SWOT Analysis (Amgen)
Fig. 16 SWOT Analysis (Otsuka)
Fig. 17 SWOT Analysis (Takeda)
